Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 86 |
| Active Pipeline (Recruiting Now) | 41 (17) |
| Completed vs Stopped Early | 22 / 0 (0.0%) |
| Median Closed Actual Enrollment | 452 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality | 28 |
| Liaocheng People's hospital | Liaocheng, Shandong | 7 |
| The First Hospital of Jilin University | Changchun, Jilin | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06157502 | Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) | Phase III | RECRUITING |
| NCT04078737 | Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II | Phase III | COMPLETED |
| NCT05439356 | Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3) | Phase III | COMPLETED |
| NCT06316570 | Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke | Phase III | COMPLETED |
| NCT04797013 | Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Beijing Tiantan Hospital Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.